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  M
etabolomics (also referred 
to as metabonomics) is the 
comprehensive study of 
the metabolome, the repertoire of 
biochemicals (or small molecules) 
present in cells, tissue, and body ﬂ  uids. 
The study of metabolism at the global 
or “-omics” level is a new but rapidly 
growing ﬁ  eld that has the potential to 
have an impact upon medical practice 
[1–4]. At the center of metabolomics 
is the concept that an individual’s 
metabolic state is a close representation 
of the individual’s overall health status. 
This metabolic state reﬂ  ects what has 
been encoded by the genome and 
modiﬁ  ed by environmental factors. 
    Today, clinicians capture only a very 
small part of the information contained 
in the metabolome, as revealed by a 
deﬁ  ned set of blood chemistry analyses 
to deﬁ  ne health and disease states. 
Examples include measuring glucose 
to monitor diabetes and measuring 
cholesterol for cardiovascular health. 
Such a narrow chemical analysis could 
potentially be replaced in the future 
with a metabolic signature that captures 
global biochemical changes in disease 
and upon treatment. 
    Such metabolic signatures could 
provide: (1) prognostic, diagnostic, and 
surrogate markers for a disease state; 
(2) the ability to subclassify disease; 
(3) biomarkers for drug response 
phenotypes (pharmacometabolomics); 
and (4) information about mechanisms 
of disease. Indeed, sophisticated 
metabolomic analytical platforms and 
informatics tools have recently been 
developed that make it possible to 
deﬁ  ne initial metabolic signatures for 
several diseases [5–12]. 
  Biochemical  Changes 
in Schizophrenia
    A new study in   PLoS Medicine   by 
Elaine Holmes and colleagues is an 
early metabolomics experiment that 
attempts to identify biomarkers to 
assist in the diagnosis and treatment 
of schizophrenia [13]. The authors 
explore the use of a nuclear 
magnetic resonance–based metabolic 
proﬁ  ling platform (metabonomics) 
to deﬁ  ne biochemical changes in 
the cerebrospinal ﬂ  uid (CSF) and 
biomarkers in ﬁ  rst onset, drug-naïve 
patients with schizophrenia, and 
upon treatment with antipsychotic 
medications. 
    Schizophrenia is a devastating mental 
illness that is poorly understood at the 
molecular level [14]. There are no 
validated biomarkers of schizophrenia 
that establish diagnosis or reliably 
predict response to treatment. While 
antipsychotic therapies were proven 
effective in short-term trials, most 
patients discontinue treatment over 
time for lack of effectiveness or 
development of side effects, and not 
all patients respond similarly to these 
medications [15]. An important clinical 
feature of schizophrenia is that patients 
have a greater risk than the general 
population for developing obesity 
and metabolic disorders such as type 
2 diabetes mellitus and the metabolic 
syndrome [16]. 
    Holmes and colleagues found an 
abnormal biochemical proﬁ  le in 
patients with schizophrenia or brief 
psychotic disorder when compared 
with healthy controls. The loading 
coefﬁ  cients indicated that glucose, 
acetate, alanine, and glutamine 
resonances were predominantly 
responsible for separation of 
disease and control populations. 
Upon treatment with antipsychotic 
medications, this aberrant metabolic 
signature reverted to normal in half of 
the patients in their study. Their data 
suggest that early treatment of a ﬁ  rst 
psychotic episode seems to help revert 
abnormal metabolic states to normal. 
    While these preliminary data are 
derived from only a small patient 
population (54 patients with 
schizophrenia or brief psychotic 
disorder) using one metabolomics 
platform that captures only a 
subset of the metabolome, the 
study nevertheless exempliﬁ  es the 
potential for metabolomics in the 
study of human disease. Impairments 
in glucose and acetate point to 
pathways of energy metabolism and 
lipid biosynthesis as possibly being 
impaired in schizophrenia. Further 
longitudinal studies, including 
randomization to treatment with 
larger patient populations, are needed 
to deﬁ  ne effects of each drug on 
metabolic signatures. When deﬁ  ning 
disease signatures and biomarkers for 
schizophrenia, patients and controls 
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  There are no validated 
biomarkers of 
schizophrenia that 
establish diagnosis or 
reliably predict response 
to treatment. 
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must be very carefully matched; 
possible confounding effects of other 
medications and disease states have 
to be considered, as these could 
contribute to signatures and biomarker 
development. Replication and validation 
studies are needed in independent sets 
of patients and controls. 
  Future  Metabolomics  Studies
    Since no one metabolomics platform 
can capture the entire metabolome, the 
use of complementary metabolomics 
platforms could better deﬁ  ne impaired 
pathways and highlight biomarkers. For 
example, by using a targeted lipidomics 
platform that reports back on more 
than 300 lipids, our group was able to 
highlight global lipid perturbations 
associated with schizophrenia and the 
use of three antipsychotic medications 
(unpublished data). Ongoing 
studies with an electrochemistry-
based metabolomics platform are 
starting to deﬁ  ne global changes 
in neurotransmitter pathways in 
schizophrenia. 
    Collectively, these metabolomics 
tools could provide valuable 
information about disease pathogenesis 
and result in metabolic signatures that 
could be developed as biomarkers for 
disease and progression. Comparative 
studies in CSF and plasma could help 
map central and peripheral changes 
in metabolism in schizophrenia and 
enable a more accessible way for 
biomarker development. 
    The observation that not all patients 
correct their aberrant metabolic 
proﬁ  les upon treatment with 
antipsychotics suggests that metabolic 
proﬁ  ling could be used as an additional 
tool to complement clinical evaluation 
in deﬁ  ning drug response phenotypes 
and variation in response to therapy. 
Pharmacometabolomics is emerging 
as a new ﬁ  eld that could complement 
pharmacogenomics by providing 
precise intermediate phenotypes for 
drug response. Metabolomics could 
add signiﬁ  cantly to our understanding 
of both pharmacokinetic and 
pharmacodynamic properties of drugs. 
While in Holmes and colleagues’ study 
drug effects were classiﬁ  ed based on 
whether the antipsychotic was atypical 
or typical, a more precise mapping 
of the effect of each antipsychotic 
alone is warranted. Different atypical 
antipsychotics might have different 
mechanisms of action and solicit 
different responses in different 
patients. 
    Metabolomics has the potential 
to map early biochemical changes 
in disease and hence provide an 
opportunity to develop predictive 
biomarkers that can trigger earlier 
interventions. The authors suggest that 
early treatment seems to correct more 
effectively for biochemical changes 
noted in schizophrenia, allowing 
reversal to a more normal metabolic 
state. 
  Conclusion
    Holmes and colleagues’ study illustrates 
the promise of metabolomics for the 
study of human disease. Metabolomics 
builds on more than a hundred years of 
ﬁ  ndings in biochemistry and takes one 
of the oldest sciences to an “-omics” 
level. Data from metabolomics, when 
combined with other omics data, could 
enable a more global systems approach 
to the study of human disease.   
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